You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
三葉草生物-B(02197.HK):中期溢利達6.51億元 集團業務實現扭虧為盈
格隆匯 08-23 08:05

格隆匯8月23日丨三葉草生物-B(02197.HK)發佈公吿,截至2023年6月30日止六個月,其他收入及收益由上年同期的人民幣1180萬元增加人民幣24.99億元至人民幣25.108億元,主要是因為基於2023年6月30日前隨附條件已獲滿足,從流行病防範創新聯盟(“CEPI”)收到的人民幣24.941億元的資金確認為其他收入。集團業務實現扭虧為盈,由上年同期的虧損人民幣11.361億元轉為截至2023年6月30日止六個月的溢利人民幣6.506億元,主要歸因於確認為其它收入的CEPI資金以及研發及行政支出減少約50%,部分被計提的存貨撥備所抵銷。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account